ArticleBone marrow transplantation2026
Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).
Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous hematopoietic stem cell transplantation (aHSCT) has evolved as a treatment for severe autoimmune diseases (ADs). Advances in transplant procedures and supportive care have led to improvements in long-term survival but there is limited data on 'late effects'. The aim of this retrospective EBMT registry study is to assess the incidence of 'late effects' after aHSCT for ADs. All EBMT centres were invited and data were received for 579 patients (median age 37 years, range 2.7-73.8), who received aHSCT between 1997 and 2016. Median follow-up was 89 months (IQR 82.4-95.5). Indications included multiple sclerosis (MS, 46.8%), systemic sclerosis (SSc, 28.7%), Crohn's disease (CD, 12.6%), systemic lupus erythematosus (SLE, 2.4%) and other ADs (9.5%). Conditioning was mainly based on Cy/ATG (51.9%) or BEAM/ATG (25.3%). At 10-years, the cumulative incidence of secondary ADs was 10.3% (95% CI: 7.7-13.3), new post-transplant cancers 4.1% (95% CI: 2.2-6.8), endocrine complications 16.2% (95% CI: 12.6-20.1), and cardiovascular complications 14.7% (95% CI: 11.2-18.6). Median time to endocrine events (15.4 months) was generally sooner than median times to secondary ADs (24.5 months) and cardiovascular (25.3 months), with new cancers occurring relatively late (median time 81.7 months). Overall, at 10-years, progression-free survival (PFS) was 40.1% (95% CI: 34.7-45.4), overall survival (OS) 83.5% (95% CI: 79.3-86.9) and non-relapse mortality (NRM) 5.0% (95% CI: 3.2-7.4). By multivariate analysis, secondary ADs were relatively higher in CD vs SSc (HR = 4.93, p = 0.01) and MS (HR = 2.05, p = 0.055), while cardiovascular complications were significantly increased in SSc compared to MS (HR = 8.85, p < 10
Indexed as
Identifiers
42509429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.